To the Editor:Neisseria gonorrboeae(NG)with decreased susceptibility to ceftriaxone(CRO)and cefixime,the last option for first-line anti-microbial monotherapy,was spread globally.Until now,more than ten clinical treat...To the Editor:Neisseria gonorrboeae(NG)with decreased susceptibility to ceftriaxone(CRO)and cefixime,the last option for first-line anti-microbial monotherapy,was spread globally.Until now,more than ten clinical treatment failures with CRO have been reported with minimum inhibitory concentration(MIC)range as 0.5 to 2.0 mg/L.CRO,thereafter,is no longer recommended as mono-therapy for gonorrhea.Instead,dual therapy that combines CRO with azithromycin is currently exerted in many countries including China.However,the first treatment failure to dual therapy(500 mg CRO plus 1 g azithromycin)was identifed in 2014 in London.展开更多
基金This study was supported by grants from the Natural Science Foundation of Guangdong(No.2018A0303130011)the Medical and Health Technology Projects of Guangzhou(No.20171A011284)and the Medical Science and Technology Research Foundation of Guangdong Province(No.A2017239).
文摘To the Editor:Neisseria gonorrboeae(NG)with decreased susceptibility to ceftriaxone(CRO)and cefixime,the last option for first-line anti-microbial monotherapy,was spread globally.Until now,more than ten clinical treatment failures with CRO have been reported with minimum inhibitory concentration(MIC)range as 0.5 to 2.0 mg/L.CRO,thereafter,is no longer recommended as mono-therapy for gonorrhea.Instead,dual therapy that combines CRO with azithromycin is currently exerted in many countries including China.However,the first treatment failure to dual therapy(500 mg CRO plus 1 g azithromycin)was identifed in 2014 in London.
